| 18th week of 2016 patent applcation highlights part 24 |
| Patent application number | Title | Published |
|---|
| 20160122399 | DIG-303 INSECTICIDAL CRY TOXINS - DIG-303 insecticidal toxins, polynucleotides encoding such toxins, use of such toxins to control pests, and transgenic plants that produce such toxins are disclosed. | 2016-05-05 |
| 20160122400 | POLYPEPTIDES WITH PERMEASE ACTIVITY - The invention relates to a polypeptide having one or more substitution at a position corresponding to position 339 or 376 of SEQ ID NO: 59, wherein the polypeptide is a member of the Major Facilitator Superfamily (MFS). In an embodiment, the substitution is at position corresponding to 376 and wherein the amino acid at that position is replaced by an amino acid that has a van der Waals volume of 80 to 138 Å | 2016-05-05 |
| 20160122401 | AGENTS FOR PREVENTING AND TREATING HIV AND OTHER VIRAL INFECTIONS - An agent for preventing and/or treating HIV and other viral infections. The agent in particular comprises at least one peptide, including an amino acid sequence, which is suitable for preventing fibrils associated with Alzheimer's disease, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections. | 2016-05-05 |
| 20160122402 | RETRO POLYPEPTIDES FOR ACTIVATION IMMUNITY TO CANCER AND VIRAL INFECTION - A polypeptide that drives T cell proliferation and differentiation, and methods and agents for modulating the expression and/or function of the polypeptide. Agents that up regulate the expression and/or function of the polypeptide are useful in the treatment or prevention of diseases and disorders that would benefit from stimulation of T cell proliferation and/or differentiation, such as cancer and chronic viral infections. Agents that down-regulate the expression and/or function of the polypeptide are useful in the treatment or prevention of diseases, disorders and conditions involving unwanted or excessive proliferation and/or differentiation of T cells, such as autoimmune and inflammatory diseases. Isolated T cells containing an expression vector encoding a polypeptide is also disclosed. Such T cells may be used in adoptive cell transfer therapies. | 2016-05-05 |
| 20160122403 | GHRELIN SPLICE VARIANT FOR TREATING NEURONAL DAMAGE,NEURODEGENERATIVE DISEASE, PARKINSONS DISEASE, ALZHEIMERS DISEASE, AND/OR DEPRESSION - The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof, or a ghrelin splice variant-like compound for the preparation of a medicament for one or more of: treatment and/or prevention of neuronal damage and/or neurodegeneration and, prophylaxis or treatment of neuronal damage and/or neurodegenerative disease, Parkinson's disease, Alzheimer's disease, depression stimulation of neuronal activity. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds. | 2016-05-05 |
| 20160122404 | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE FUNCTION - Compositions and methods for modulating immune cell function and Nedd-4 family member signaling are disclosed. | 2016-05-05 |
| 20160122405 | HOMEODOMAIN FUSION PROTEINS AND USES THEREOF - Provided herein are fusion proteins comprising a homeodomain fusion protein domain and a transcription modulator domain for treatment of various diseases or disorders such as cancer. The homeodomain fusion protein domain binds to a target gene and the transcription modulator domain either activates or represses gene transcription. The present invention also relates to polynucleotides encoding the fusion proteins, vectors comprising the polynucleotides, cells comprising the polynucleotides, vectors, or fusion proteins. Also provided are methods of use and compositions for delivery of the fusion proteins. | 2016-05-05 |
| 20160122406 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE - This invention relates to analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC | 2016-05-05 |
| 20160122407 | Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors - The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor. | 2016-05-05 |
| 20160122408 | Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors - The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Gaicctin-3 and a proteasome inhibitor. | 2016-05-05 |
| 20160122409 | ERYTHROFERRONE AND ERFE POLYPEPTIDES AND METHODS OF REGULATING IRON METABOLISM - Disclosed herein are polypeptides which are capable of modulating the amount of hepcidin in subjects. Also disclosed are compositions and methods for treating diseases and disorders of iron metabolism. | 2016-05-05 |
| 20160122410 | INTERFERON ALPHA 2B VARIANTS - The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon α 2b (IFNα2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFNα2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFNα2b. | 2016-05-05 |
| 20160122411 | CARTILAGE-BINDING FUSION PROTEINS - Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided. | 2016-05-05 |
| 20160122412 | COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND - The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of TNF SuperFamily (TNFSF) ligands. The TNFSFs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of CD40 ligand (CD40L, TNFSF5) is provided. Other similar fusion proteins are also disclosed. The fusion proteins can be delivered to a host as isolated proteins, as nucleic acids used directly in DNA vaccination or carried and expressed by a viral vector such as adenovirus. In addition to use as a vaccine to prevent or ameliorate disease caused by an infectious agent, compositions of the invention may be used for the treatment of ongoing infection or for cancer immunotherapy. | 2016-05-05 |
| 20160122413 | METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN - Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment, homologous or orthologues protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated. | 2016-05-05 |
| 20160122414 | METHOD FOR EXTRACTING RECOMBINANT HUMAN SERUM ALBUMIN FROM TRANSGENIC RICE GRAIN - A method for extracting recombinant human serum albumin (rHSA) from transgenic rice grain is provided, comprising the steps of: 1) grinding dehusked rice containing rHSA into milled rice grain with a fineness of 80˜120 mesh, which is mixed with a extraction buffer in a wily ratio of 1:5, then extracting at 5560° C. for 1˜3 hours to obtain mixture 1; said extraction buffer comprises 10˜30 mM phosphate buffer, 10˜20 mM sodium acetate, 1530 mM ammonium sulfate and 5˜20 mM sodium caprylate and has a pH of 6.5˜8; 2) adjusting the pH of mixture I to 4.0˜4.5, followed by precipitating at room temperature for 3˜12 hours to obtain mixture 3) filtering the mixture 11 and collecting the filtrate, to obtain a solution containing high concentration of rHSA. The concentration of rHSA in the resultant solution is 650˜660 μg/mL, which increases by 1.15 times comparing to the extraction amount before improvement, and the amount of non-target protein is reduced by 2.46 times. The method provides a basis for subsequent purification of rHSA. | 2016-05-05 |
| 20160122415 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer. | 2016-05-05 |
| 20160122416 | ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR - A method for conjugating an isolated antibody to a label or derivatisation reagent, which method comprises contacting the antibody with an activated label or activated derivatisation reagent, or contacting the antibody with the label or derivatisation reagent in the presence of an antibody conjugation reagent, in a buffer system which comprises a monocarboxylic acid buffer compound other than glycine, bearing an amine substituent at the alpha or beta position. | 2016-05-05 |
| 20160122417 | Engineered Intein for Improved Production of Protein-Intein Fusions - The invention discloses engineered non-self-cleaving inteins derived from Mxe GyrA inteins and methods of using such inteins to chemically modify proteins. | 2016-05-05 |
| 20160122418 | HUMAN MONOCLONAL ANTIBODY SPECIFIC FOR THE F PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS (RSV) - This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10 | 2016-05-05 |
| 20160122419 | ALTERNATIVE PATHWAY SPECIFIC ANTIBODIES FOR TREATING HEMOLYTIC DISEASES - A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9. | 2016-05-05 |
| 20160122420 | ANTIBODY DISPLAY - The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises a single-domain antibody fragment in the el loop. | 2016-05-05 |
| 20160122421 | METHODS OF TREATING A TAUOPATHY - The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods. | 2016-05-05 |
| 20160122422 | TREATMENT OF TAUOPATHIES - The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau. | 2016-05-05 |
| 20160122423 | BLOOD MARKERS FOR DIAGNOSING EPITHELIUM DERIVED CANCERS AND MONOCLONAL ANTIBODIES THEREOF - The present invention provides uses of cytokeratins as markers for diagnosing epithelium derived cancers. The present invention provides cancer-related epitopes of cytokeratins and monoclonal antibodies which specifically recognize the epitopes. The present invention also provides methods for the early screen, diagnosis or prognosis of epithelium derived cancers in subjects, methods for the evaluation of therapeutic effect of related medicaments or therapies, and kits for accomplishing the methods. | 2016-05-05 |
| 20160122424 | METHODS FOR TREATING DIABETES - Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-β) superfamily of structurally-related growth factors (e.g., GDF-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as GLUT4 and GLUT 1, in a subject by administering an inhibitor of GDF-8. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an inhibitor of GDF-8. | 2016-05-05 |
| 20160122425 | Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 2016-05-05 |
| 20160122426 | ANTI-VEGF ANTIBODY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, DIAGNOSING OR TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES, CONTAINING SAME - A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer. | 2016-05-05 |
| 20160122427 | Protein Production Method - Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed. | 2016-05-05 |
| 20160122428 | FD CHAIN GENE OR L CHAIN GENE CAPABLE OF INCREASING SECRETION AMOUNT OF FAB-TYPE ANTIBODY - It is an object of the present invention to provide a method for producing a low-molecular-weight antibody such as a Fab-type antibody, using yeast as a host, wherein the method is able to produce the low-molecular-weight antibody with high productivity. According to the present invention, there is provided a gene comprising a nucleotide sequence encoding an amino acid or an amino acid sequence capable of increasing the secretion amount of a Fab-type antibody at the 3′-terminus of a nucleotide sequence encoding the amino acid sequence of the Fd chain or L chain of an antibody. | 2016-05-05 |
| 20160122429 | ANTI-TNF- / ANTI-IL-23 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNFα) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNFα and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis. | 2016-05-05 |
| 20160122430 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma. | 2016-05-05 |
| 20160122431 | B7-DC BINDING ANTIBODY - An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma. | 2016-05-05 |
| 20160122432 | ANTI-HER2 SINGLE DOMAIN ANTIBODIES, POLYPEPTIDES COMPRISING THEREOF AND THEIR USE FOR TREATING CANCER - The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer. | 2016-05-05 |
| 20160122433 | ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer. | 2016-05-05 |
| 20160122434 | ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY - The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of Vγ9Vδ2 T cells. | 2016-05-05 |
| 20160122435 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2016-05-05 |
| 20160122436 | SINGLE CHAIN BINDING MOLECULES COMPRISING N-TERMINAL ABP - The present invention relates to a single chain binding molecule comprising at least three binding domains, wherein the first binding domain is capable of binding to serum albumin and is positioned at the N-terminus of the second binding domain, said second binding domain is capable of binding to a cell surface molecule on a target cell and the third binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention relates to methods for the production of such binding molecule, a nucleic acid sequence encoding it, a vector comprising said nucleic acid sequence and a host cell expressing the binding molecule of the invention. Furthermore, the invention relates to a pharmaceutical composition comprising a binding molecule of the invention, methods of treatment comprising the step of administering a binding molecule of the invention and the medical use of a binding molecule of the invention. | 2016-05-05 |
| 20160122437 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 2016-05-05 |
| 20160122438 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 2016-05-05 |
| 20160122439 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 2016-05-05 |
| 20160122440 | MODIFIED WOOD FIBRES FOR MANUFACTURE IN COMPOSITES - A method for the acylation of lignocellulose by exposing the lignocellulose to an acylation agent in a closed vessel. | 2016-05-05 |
| 20160122441 | CATIONIC GROUP-CONTAINING CELLULOSE ETHER - Provided is a cationic group-containing cellulose which, when incorporated in a hair wash composition, is able to give an excellent smootheness feeling and its sustained feeling in rinsing and give a good coat feeling, and which, when incorporated in a skin cleanser composition, is able to give an excellent moist feeling to the skin after washing and drying, and also provided are a surfactant composition, a hair wash composition, a skin cleanser composition, a hair conditioner composition and a hair treatment composition containing the cellulose ether. [1] A cationic group-containing cellulose ether, which has a main chain derived from an anhydroglucose, and in which the degree of substitution with a cationized oxyalkylene group per the anhydroglucose unit is from 0.01 to 1.0, the degree of substitution with a glycerol group is from 0.5 to 5.0, and the degree of substitution with a group that contains a branched hydrocarbon group having from 8 to 18 carbon atoms and has a specific structure is from 0.001 to 0.2; [2] a surfactant composition containing the cationic group-containing cellulose ether, a surfactant and water; [3] a hair wash composition, a skin cleanser composition, a hair conditioner composition and a hair treatment composition containing the cationic group-containing cellulose ether, a surfactant and water. | 2016-05-05 |
| 20160122442 | Process for Hydrolysis of Starch - The present invention relates to a process for enzymatic hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below or just above the initial gelatinization temperature of said granular starch. | 2016-05-05 |
| 20160122443 | PROCESS FOR THE REMOVAL OF CONTAMINATION FROM A RAW MATERIAL - The present invention relates to a process for the removal of contamination from a raw material comprising a desirable material, such as chitin and/or chitosan. The process comprises mixing a raw material with a liquid, wherein the raw material comprises at least one contaminant and at least one desirable material, and wherein the at least one desirable material is capable of absorbing the liquid; and allowing the at least one contaminant and at least one desirable material to separate in a separation container. | 2016-05-05 |
| 20160122444 | CHITIN-GLUCAN COMPLEXES AND METHOD FOR THE PREPARATION THEREOF FROM CHITIN-RICH BIOMATERIALS - The present invention is related to a novel process for the preparation of chitin-glucan or chitosan-glucan complexes from raw materials of biological origin rich in chitin, such as mycelium of micro-fungi and exoskeletons of crustaceans, where the product obtained presents a chitin proportion between 19 and 55% and average molecular weight between 1.7 and 155 kDa. | 2016-05-05 |
| 20160122445 | ENZYMATICALLY POLYMERIZED GELLING DEXTRANS - Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed. | 2016-05-05 |
| 20160122446 | REVERSIBLE HEPARIN MOLECULES AND METHODS OF MAKING AND USING THE SAME - Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine. | 2016-05-05 |
| 20160122447 | POLYMERIC ACID CATALYSTS AND USES THEREOF - Polymers useful as catalysts in non-enzymatic saccharification processes are provided. Provided are also methods for hydrolyzing cellulosic materials into monosaccharides and/or oligosaccharides using these polymeric acid catalysts. | 2016-05-05 |
| 20160122448 | POLYETHYLENE COMPOSITION FOR PIPE AND PIPE COATING APPLICATIONS - The present application relates to a polyethylene composition comprising a base resin being a copolymer of ethylene with at least one alpha olefin comonomer having from 3 to 12 carbon atoms, the base resin having a density of more than 940.0 kg/m | 2016-05-05 |
| 20160122449 | POLYPROPYLENE FOR FILM APPLICATIONS - Propylene copolymer having a comonomer content in the range of 2.5 to 11.5 mol.-% and a melt flow rate MFR | 2016-05-05 |
| 20160122450 | SYNTHESIS OF A SUBSTITUTED FURAN - The present invention provides a polymer comprising an aliphatic backbone having a plurality of aromatic rings bonded thereon, said plurality of aromatic rings comprising a first aromatic ring type that has an alkyl halide group substitution on the aromatic ring and a second aromatic ring type that has an optionally substituted ammonium halide group substitution on the aromatic ring. The present invention also provides a method for making an optionally substituted furan, the method comprising the step of subjecting a sugar to a dehydration reaction in the presence of a catalyst comprising said polymer. | 2016-05-05 |
| 20160122451 | ENZYME-CATALYZED SYNTHESIS OF SITE-SPECIFIC AND STOICHIOMETRIC BIOMOLECULE-POLYMER CONJUGATES - Methods for producing polypeptide-polymer conjugates include attachment of an initiator agent to a polypeptide specifically at the C-terminus of the polypeptide using a sortase enzyme and in situ polymerization of a polymer from the C-terminus. The polypeptide-polymer conjugates may have desirable pharmacological properties and may be used therapeutically. | 2016-05-05 |
| 20160122452 | Ethylene-Propylene Copolymeric Compositions With Long Methylene Sequence Lengths - This invention relates to methods to prepare and compositions pertaining to branched ethylene-propylene copolymers that include at least 50% ethylene content by weight as determined by FTIR; a g′ | 2016-05-05 |
| 20160122453 | Methods of Catalyst Activation - A method comprising preparing a multi-component catalyst system comprising a catalyst and a cocatalyst, and adjusting the level of at least one component of the catalyst system to maintain a user-desired level of catalyst activity throughout a process, wherein the component comprises a catalyst activator and wherein the catalyst activator comprises the catalyst or the cocatalyst. A method comprising contacting a polymerization catalyst system comprising a Ziegler-Natta catalyst and a cocatalyst with a catalyst activator at least twice during a polymerization process, wherein the polymerization process is carried out in a reactor system comprising multiple reactor types. | 2016-05-05 |
| 20160122454 | Polymers With Improved Toughness and ESCR for Large-Part Blow Molding Applications - Disclosed herein are ethylene-based polymers having a density greater than 0.945 g/cm | 2016-05-05 |
| 20160122455 | METAL COMPLEX WITH A BRIDGED CYCLOPENTADIENYL AMIDINE LIGAND - The present invention relates to a new metal complex of the formula (1) | 2016-05-05 |
| 20160122456 | PHOTORESIST COMPOSITIONS AND METHOD OF PREPARING THE SAME - The present invention provides a photoresist composition and a method of preparing the same. The photoresist composition includes a color polymer that is obtained by dye molecules grafted to a polymer molecule through chemical bonds. The photoresist composition utilizes the color polymer to replace conventional pigments to preclude conventional problems of difficult to disperse pigments in the photoresist composition, poor contrast and brightness. Since the color polymer has brilliant color, high penetration, good thermal and light stabilities, so that the photoresist composition of the present invention has better color developing effect, preferred thermal and light stabilities. The present invention provides a method of preparing a photoresist composition which reduces components in the photoresist composition and simplifies preparation process of the photoresist composition, the photoresist composition obtained thereby has better color developing effect, also has preferred thermal and light stabilities. | 2016-05-05 |
| 20160122457 | NITRILE GROUP-CONTAINING COPOLYMER RUBBER, CROSS-LINKABLE RUBBER COMPOSITION, AND CROSS-LINKED RUBBER - A nitrile group-containing copolymer rubber which has a hydroxyl group, carboxyl group, or carbon-carbon double bond at an end carbon atom or on a carbon atom which bonds with the end carbon atom is provided. The nitrile group-containing copolymer rubber is preferably obtained by a metathesis reaction. A nitrile group-containing copolymer rubber which is excellent in cross-linkability can be provided. | 2016-05-05 |
| 20160122458 | GENERATION OF AMPHIPHILIC NETWORK WITH AN ABILITY TO DISTINGUISH THE TRANSPORT OF IGG AND INSULIN - A method of preparing an amiphiphilic co-network comprising preparing a molecularly-bimodal crosslinkable amphiphilic graft by polymerizing a dihydrocarbylacrylamide monomer in the presence of a first asymmetric-telechelic polydihydrocarbylsiloxane monomer mixture and a second asymmetric-telechelic polydihydrocarbylsiloxane monomer mixture where the molar mass ratio between average molar mass of the first asymmetric-telechelic monomer mixture polydihydrocarbylsiloxane and average molar mass of the second asymmetric-telechelic monomer mixture polydihydrocarbylsiloxane is between 1:2 and 1:20; and crosslinking the molecularly-bimodal crosslinkable amphiphilic graft with a siloxane compound that includes at least two Si—H bonds. | 2016-05-05 |
| 20160122459 | METHOD FOR PRODUCING POLYACETAL COPOLYMER - A high-quality polyacetal copolymer produced by a simple process in an economical manner. The process includes supplying a raw material including trioxane and the like to a reaction device; setting the polymerization environmental temperature to no more than 100° C. until the reaction device conversion rate becomes 0.5, and then carrying out further polymerization; vaporizing and separating unreacted monomers from the reaction mixture at an environmental temperature of at least 115° C. and less than 140° C.; supplying the separated monomers to the raw material supply; and recovering the polyacetal copolymer from the reaction mixture. | 2016-05-05 |
| 20160122460 | POLYMER WITH URETHANE OR THIOURETHANE UNITS FOR USE, IN PARTICULAR, AS AN ADHESION PRIMER FOR BONDING METAL TO RUBBER - A polymer has urethane or thiourethane units, which can be used, in particular, as an adhesion primer for the adhesive bonding of metal or glass to rubber. The polymer comprises base units comprising at least a sub-unit of formula —X | 2016-05-05 |
| 20160122461 | COMPOSITION FOR OPTICAL MATERIAL - According to the present invention, a composition for an optical material contains a compound (a), a compound (b), and a polyisocyanate compound (c), and can suppress the generation of striae defects. The compound (a) is a compound having a structure represented by formula (1). | 2016-05-05 |
| 20160122462 | FAST RECOVERY SOFT THERMOPLASTIC POLYURETHANES - The thermoplastic polyurethane compositions described herein have very good recovery properties, rebound resilience, or both, while also having good softness (i.e. low hardness). It has been difficult to provide thermoplastic polyurethane compositions with this combination of properties. Some compositions described herein also provide low haze and/or good clarity properties. These combination of properties make the thermoplastic polyurethane compositions described herein useful materials for application that require fast recovery, good rebound resilience, or both while also requiring soft materials, and in some embodiments low haze and/or good clarity. | 2016-05-05 |
| 20160122463 | Process for preparing low-viscosity allophanates containing actinically curable groups - The present invention provides a process for preparing radiation-curing allophanates having residual monomer contents of less than 0.5% by weight and an NCO content of less than 1% by weight, wherein (A) compounds containing isocyanate groups, (B) hydroxy-functional compounds which contain groups which react, with polymerization, with ethylenically unsaturated compounds on exposure to actinic radiation (radiation-curing groups) and (C) optionally further compounds containing NCO-reactive groups, also optionally in the presence of a catalyst, are used to form NCO-group-containing urethanes having radiation-curing groups, which are subsequently reacted, without further addition of compounds containing isocyanate groups, in the presence of an allophanatization catalyst, the ratio of NCO groups of the compounds from A) to the OH groups of the compounds from B) and, where used, C) being 1.45:1.0 to 1.1:1.0. | 2016-05-05 |
| 20160122464 | SOLVENT FREE POLYISOBUTYLENE BASED POLYURETHANES - A biocompatible polyisobutylene urethane, urea, and urethane/urea copolymer including hard segments, soft segments and that is free of urethane, urea or urethane/urea solvents. The hard include diisocyanate residue. The soft segments include at least one polyisobutylene diol or diamine and optionally a polyether diol. | 2016-05-05 |
| 20160122465 | SOFT THERMOPLASTIC POLYURETHANE ELASTOMERS AND PROCESS FOR THEIR PREPARATION - The present invention discloses a thermoplastic polyurethane comprising substantially no plasticizers and having a Shore A hardness of 60 or less, which is prepared by a one-step polymerization of i) linear polyol, ii) organic diisocyanate and iii) glycol chain extender mainly comprising ethylene glycol and/or 1,3-propanediol; wherein the linear polyol (i) has a number average molecular weight within the range of from 1.5×10 | 2016-05-05 |
| 20160122466 | CURABLE EPOXY RESIN COMPOSITION AND CURED PRODUCT THEREOF, DIOLEFIN COMPOUND AND PRODUCTION METHOD THEREFOR, AND PRODUCTION METHOD FOR DIEPOXY COMPOUND - An object of the present invention is to provide a curable epoxy resin composition, which is cured to provide a cured product having a high glass-transition temperature and particularly having excellent balance between heat resistance and transparency. | 2016-05-05 |
| 20160122467 | Amidopolyamines with Enhanced Gel-Time for Elevated Temperature Applications - An epoxy curing agent is disclosed that can be obtained by reacting at least one carboxylic acid with at least one polyamine. The disclosed curing agent can be obtained by preparing an amidoamine with about 0.15 to about 0.30 molar excess of carboxylic acid. | 2016-05-05 |
| 20160122468 | Esters Of Oligo-Hydroxycarboxylic Acids And Use Thereof - Esters of oligo-hydroxycarboxylic acids have the general formula ( ): | 2016-05-05 |
| 20160122469 | Functional norbornanyl ester derivatives, polymers and process for preparing same - This invention relates to the new functional norbornanyl ester derivative and/or polymer compositions which are easily obtainable by reacting the Diels-Alder adduct of appropriate dienes and dienophiles with carboxylic acids. In particular, this invention relates to a new process for making cyclic chemical raw materials suitable for production coating, ink, adhesive, plasticizer, thermoplastic or thermosetting plastic and functional polymers. | 2016-05-05 |
| 20160122470 | WAVELENGTH-CONVERTING POLYMERS, METHOD FOR FABRICATING THE SAME, AND WAVELENGTH-CONVERTING DEVICES EMPLOYING THE SAME - A wavelength-converting polymer, a method for fabricating the same and a wavelength-converting device employing the same are provided. The wavelength-converting polymer has a chemical structure represented by formula (I): | 2016-05-05 |
| 20160122471 | Polymeric Plasticizer Compositions - The present invention relates to polymeric plasticizer compositions made from an aromatic acid source, a glycol, and a C | 2016-05-05 |
| 20160122472 | TITANIUM DIOXIDE PIGMENT AND MANUFACTURING METHOD - A novel polymer comprising a water soluble polymer backbone, at least one functional group attached to the polymer backbone and having an affinity for titanium dioxide, and at least one hydrophobic functional group attached to the polymer backbone and having an affinity for latex is provided. A titanium dioxide pigment composition is provided including the novel polymer is also provided. Also provided is a method of manufacturing a titanium dioxide pigment composition that includes the novel polymer. | 2016-05-05 |
| 20160122473 | ACRYLATED OR METHACRYLATED URETHANE OLIGOMER WITHOUT ISOCYANATE - The invention relates to a monofunctional or multifunctional acrylated or methacrylated urethane oligomer where said urethane bond is obtained without use of isocyanate and by the carbonate-amine reaction between a cyclic carbonate and a monoamine or polyamine, with subsequently the conversion of the hydroxyls in the β position with respect to the urethane bond into ester-acids by reaction with a cyclic anhydride, which reaction is followed by the conversion of said acid functional groups into acrylated or methacrylated end groups by reaction with a polyepoxide compound in the presence of acrylic or methacrylic acid. | 2016-05-05 |
| 20160122474 | METHOD FOR PRODUCING POLYIMIDE PRECURSOR AND METHOD FOR PRODUCING POLYIMIDE - A method for producing a polyimide precursor, including: reacting tetracarboxylic dianhydride represented by the following General Formula (1) with a diamine compound represented by the following General Formula (2) in a compressive fluid to thereby produce a polyimide precursor represented by the following Formula (3): | 2016-05-05 |
| 20160122475 | COPOLYESTERIMIDES DERIVED FROM N,N'-BIS-(HYDROXYALKYL)-PYROMELLITIC DIIMIDE AND FILMS MADE THEREFROM - A polyester film comprising a copolyester which comprises repeating units derived from an aliphatic glycol, an aromatic dicarboxylic acid, and the monomer of formula (I): wherein n=2, 3 or 4, and wherein comonomer (I) constitutes a proportion of the glycol fraction of the copolyester. | 2016-05-05 |
| 20160122476 | Method for Preparing Dioxyheterocycle-Based Electrochromic Polymers - A method for preparing a conjugated polymer involves a DHAP polymerization of a 3,4-dioxythiophene, 3,4-dioxyfuran, or 3,4-dioxypyrrole and, optionally, at least one second conjugated monomer in the presence of a Pd or Ni comprising catalyst, an aprotic solvent, a carboxylic acid at a temperature in excess of 120° C. At least one of the monomers is substituted with hydrogen reactive functionalities and at least one of the monomers is substituted with a Cl, Br, and/or I. The polymerization can be carried out at temperature of 140° C. or more, and the DHAP polymerization can be carried out without a phosphine ligand or a phase transfer agent. The resulting polymer can display dispersity less than 2 and have a degree of polymerization in excess of 10. | 2016-05-05 |
| 20160122477 | THERMOPLASTIC COPOLYMER RESIN HAVING EXCELLENT FLAME RETARDANCY AND TRANSPARENCY AND PREPARATION METHOD THEREFOR - The present invention relates to a thermoplastic copolymer resin having an excellent flame retardancy and transparency and a preparation method therefor and, more particularly, to a thermoplastic copolymer resin having an excellent balance of physical properties such as a transparency, a fluidity, a low temperature impact strength as well as a flame retardancy, a preparation method therefor, and a molded article comprising the thermoplastic copolymer resin, in which the thermoplastic copolymer resin is obtained by copolymerizing polysiloxane having a particular structure and a branched polycarbonate oligomer. | 2016-05-05 |
| 20160122478 | HYDROPHILIC ORGANOSILANES - The present disclosure relates to compositions comprising: an organosilane having the formula: (R | 2016-05-05 |
| 20160122479 | PROCESS FOR DISPERSING PARTICLES IN FILLED RESIN COMPOSITIONS - An improved process for dispersing filler particles in a resin composition is disclosed. The filler particles, for instance electrically conductive or metal particles, are mixed with a resin material or blend of materials including a resin material to form a mixture that is subjected to an acceleration force. The acceleration force can be generated by passing the mixture through a static nozzle having particular dimensions to generate an acceleration of the mixture in the nozzle in excess of 400,000 m/sec | 2016-05-05 |
| 20160122480 | END-MODIFIED CONJUGATED DIENE POLYMER AND METHOD FOR PREPARING THE SAME - One aspect of the present invention provides an end-modified conjugated diene polymer represented by Formula 1 below: | 2016-05-05 |
| 20160122481 | POLYLACTIC RESIN COMPOSITION AND MOLDING - A polylactic resin composition, including: polylactic resin as main component, wherein in a binary image of the polylactic resin composition obtained by binarizing a phase image of a cross-section of the polylactic resin composition observed with an AFM in tapping mode based on intermediate value between maximum and minimum values of phase differences of the polylactic resin composition in free vibration, phases equal to or greater than intermediate value are dispersed in a phase less than intermediate value, and average equivalent circle diameter of the phases equal to or greater than intermediate value is from 0.2 μm to 1 μm, and wherein polylactic resin composition is detected to have at least one glass transition temperature (Tg) in a range of −20° C. or lower, and at least one glass transition temperature (Tg) in a range of 40° C. to 70° C. in a temperature elevating process of differential scanning calorimeter (DSC) measurement thereof. | 2016-05-05 |
| 20160122482 | FIBER-REINFORCED RESIN SHEET AND PROCESS FOR PRODUCING SAME - To provide a fiber-reinforced resin sheet having flame proofing property and being excellent in weather resistance and transparency, and to provide a production process thereof. | 2016-05-05 |
| 20160122483 | POLYIMIDE POLYMER, POLYIMIDE FILM HAVING THE SAME AND POLYIMIDE LAMINATE HAVING THE SAME - A polyimide polymer, polyimide film and polyimide laminate plate including the same are provided. The polyimide polymer includes Formula (I), Formula (II) and Formula (III). | 2016-05-05 |
| 20160122484 | Polyolefin Film for Use in Packaging - A polyolefin packaging film is provided. The polyolefin film is formed by a thermoplastic composition containing a continuous phase that includes a polyolefin matrix polymer and nanoinclusion additive is provided. The nanoinclusion additive is dispersed within the continuous phase as discrete nano-scale phase domains. When drawn, the nano-scale phase domains are able to interact with the matrix in a unique manner to create a network of nanopores. | 2016-05-05 |
| 20160122485 | HEAT SHRINKABLE FILM COMPOSITION COMPRISING POLYETHYLENETEREPHTALATE RESIN AND POLYESTER BASED COPOLYMER, AND HEAT SHRINKABLE FILM - There is provided a composition for forming a heat shrinkable film capable of providing a heat shrinkable film capable of having an excellent shrinkage rate and being heat-shrunk at a low temperature. The composition for forming a heat shrinkable film includes a polyethylene terephthalate (PET) resin having an inherent viscosity of 0.50 to 1.2 dl/g; and a polyester based copolymer including a dicarboxylic acid-derived residue including a residue derived from an aromatic dicarboxylic acid and a diol-derived residue including a residue derived from 4-(hydroxymethyl)cyclohexylmethyl 4′-(hydroxymethyl)cyclohexane carboxylate represented by the following Chemical Formula 1 and a residue derived from 4,4-(oxybis(methylene)bis)cyclohexane methanol represented by the following Chemical Formula 2. | 2016-05-05 |
| 20160122486 | OPTICAL FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE EMPLOYING SAME - The invention is an optical film at least containing cellulose acylate and a compound having a structure denoted by General Formula (I) described below, and a polarizing plate and a liquid crystal display device employing the optical film. | 2016-05-05 |
| 20160122487 | THERMOPLASTIC COMPOSITES - Provided are thermoplastic composites having improved flexural properties. | 2016-05-05 |
| 20160122488 | SURFACE MODIFICATION METHOD AND SURFACE MODIFICATION BODY - Provided are methods for surface-modifying a rubber vulcanizate or a thermoplastic resin, which can provide chemically fixed surfaces showing low adsorption properties or selective adsorption properties with respect to proteins and cells, as well as excellent durability, instead of coatings which have drawbacks, such as that the performance is reduced due to separation or peeling of the coating. The present invention relates to a method for surface-modifying an object made of a rubber vulcanizate or a thermoplastic resin, the method including: a step 1 of forming polymerization initiation points on the surface of the object; and a step 2 of radically polymerizing a hydrophilic monomer starting from the polymerization initiation points by irradiation with UV light having a wavelength of 300 to 400 nm to grow polymer chains on the surface of the object. | 2016-05-05 |
| 20160122489 | Rapid Solid-State Foaming - Disclosed, among other things, are ways to manufacture reduced density thermoplastics using rapid solid-state foaming and machines useful for the saturation of plastic. In one embodiment, a foaming process may involve saturating a semi-crystalline polymer such as Polylactic Acid (PLA) with high levels of gas, and then heating, which may produce a reduced density plastic having high levels of crystallinity. In another embodiment, a foaming process may produce layered structures in reduced density plastics with or without integral skins. In another embodiment, a foaming process may produce deep draw structures in reduced density plastics with or without integral skins. In yet another embodiment, a foaming process may utilize additives, blends, or fillers, for example. In yet another embodiment, a foaming process may involve saturating a semi-crystalline polymer such as Polylactic Acid (PLA) with high levels of gas, and then heating, which may produce a reduced density plastic having high levels of crystallinity. | 2016-05-05 |
| 20160122490 | Composition and Method for Making a Cavitated Bio-Based Film - Composition and method for making a multi-layer bio-based film having one or more cavitated layers. In one aspect, the multilayer flexible film has polylactic acid, an inorganic filler, and a cavitation stabilizer making up at least one film layer. In one aspect, the barrier web has a cavitated bio-based film layer. In another aspect, the print web has a cavitated bio-based film layer. | 2016-05-05 |
| 20160122491 | Polymeric Material for Use in Thermal Insulation - A polymeric material for use in thermal insulation is provided. The polymeric material is formed from a thermoplastic composition containing a continuous phase that includes a matrix polymer and within which a microinclusion additive and nanoinclusion additive are dispersed in the form of discrete domains. A porous network is defined in the material that includes a plurality of nanopores having an average cross-sectional dimension of about 800 nanometers or less. The polymeric material exhibits a thermal conductivity of about 0.20 watts per meter-kelvin or less. | 2016-05-05 |
| 20160122492 | PROPYLENE BASED RESIN COMPOSITION AND USE THEREOF - Means for solving the problems | 2016-05-05 |
| 20160122493 | Method and Flexible Lattice Foams - A method of making a foamed article, for example a foamed component for an article or footwear, comprises forming a structure of interconnected, unfoamed, thermoplastic polymeric members spaced to define openings between the thermoplastic polymeric members. The structure may be made by printing a thermoplastic polymeric material with a three-dimensional printer. The thermoplastic polymeric members are heated to a first temperature to soften the thermoplastic polymeric members and the softened thermoplastic polymeric members are infused with at least one inert gas at a first pressure greater than atmospheric pressure. The first pressure is sufficient to cause the at least one inert gas to permeate into the softened thermoplastic polymeric members. After being infused with the inert gas, the pressure is reduced to at least partially foam the thermoplastic polymeric members. | 2016-05-05 |
| 20160122494 | Foamed Plastic Material For Making Automobile Interior Parts And Manufacturing Method Thereof - Disclosed is a foamed plastic material, particularly a foamed plastic material for making automobile interior parts, and a manufacturing method of the foamed plastic material. The foamed plastic material can be used in mass production by means of known injection molding processes and an automobile interior part manufactured with such a material shows a noble quality and a soft tactile impression similar to a manual surfacing material. | 2016-05-05 |
| 20160122495 | BLOWING AGENT COMPOSITION OF HYDROCHLOROFLUOROOLEFIN - A blowing agent for thermosetting foams is disclosed. The blowing agent is predominately the trans isomer of the hydrochlorofluoroolefin (HCFO) HFCO-1233zd alone or in combination with a hydrofluoroolefin (HFO), hydrofluorocarbon (HFC), hydrochlorofluoroolefin (HCFO), a hydrocarbon. The blowing agent is effective as a blowing agent in the manufacture of thermosetting foams. | 2016-05-05 |
| 20160122496 | METHOD AND INDUSTRIAL PROCESS FOR RECOVERING RAW MATERIALS FROM PAPER-CONTAINING WASTES BY MEANS OF IONIC LIQUIDS - 2.1 At present, actual recovery of the materials in their original form from wastes such as, for example, used paper, material mixtures, composite packaging, etc. is possible only to a limited degree, if at all. The cellulose in particular is currently hardly recovered at all from paper wastes as primary material. The present invention provides a homogeneous method in which all three main components, for example of composite packaging or mixtures of composite packaging materials, specifically cellulose, plastic and metal, can be recovered in their primary form and in a quality corresponding very substantially to new material. 2.2 According to the invention, this is accomplished in a solvent-based process. This involves using a suitable ionic liquid for leaching the cellulose out of the paper component of the waste, and this step is combined with other solvent-based steps so as to give rise to a homogeneous process in which both cellulose and plastic and metal can be recovered. In the method, the plastic is likewise leached out of the waste, but with conventional solvents such as hydrocarbons. The metal is removed in solid form. According to the composition of the raw material, the process may afford only one of the abovementioned materials, two or all three. 2.3 Such a method can be used for industrial scale recovery of the abovementioned materials. | 2016-05-05 |
| 20160122497 | HIGH-DENSITY POLYETHYLENE-GRAPHENE NANOCOMPOSITES AND METHODS THEREOF - Methods of preparing high-density polyethylene (HDPE) nanocomposites by in situ polymerization with a metallocene catalyst and a methylaluminoxane co-catalyst in a solvent. The HDPE nanocomposites contain graphene nanofillers that promote the polymerization process, and are found to enhance the molecular weight, molecular weight distribution and flame retardency of the HDPE nanocomposites produced. | 2016-05-05 |
| 20160122498 | DAMPING MATERIAL, VIBRATION DAMPING MEMBER USING THE DAMPING MATERIAL, AND SEISMIC ISOLATION APPARATUS INCORPORATING THE VIBRATION DAMPING MEMBER - A vibration isolation apparatus | 2016-05-05 |
